AstraZeneca has been considered to be a leader in the race for a COVID-19 vaccine. Kangtai said last month it signed a licensing pact with AstraZeneca to produce its COVID-19 vaccine AZD1222 in mainland China. That fortune dropped by $836 million in connection with yesterday’s decline in Kangtai’s shares. His former wife Yuan Liping held Kangtai shares worth nearly $4 .6 billion before yesterday’s plunge. AstraZeneca, a European drug giant considered a global leader in the race to develop a COVID-19 vaccine, has entered into manufacturing agreements elsewhere to ramp up production.

Source: Forbes September 10, 2020 00:22 UTC